An Open-Label Multicenter Follow-up Trial of ARGX-113-1904 to Evaluate the Safety Tolerability and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus ARGX-113-1905
Recruiting
99 years or below
All
Phase
3
1 Location
Brief description of study
4.0
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
25 May 2021.
Study ID: 844792